Loading...
Tevogen Bio Holdings Inc.
TVGN•NASDAQ
HealthcareBiotechnology
$1.43
$0.02(1.42%)
Tevogen Bio Holdings Inc. (TVGN) Stock Overview
Explore Tevogen Bio Holdings Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.22
↓ 20289.72%
EPS Growth
$-0.22
↓ 23300.00%
Operating Margin
-8675.07%
↓ 605625.85%
ROE
501.22%
↓ 20289.72%
Dividend Yield
0.00%
Analyst Recommendations data is not available for TVGNAnalyst Recommendations details for TVGN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
CEO
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H.
Employees
18
Headquarters
15 Independence Blvd, Warren, NJ
Founded
2022